about
KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature.A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsDocetaxel for the treatment of prostate cancer.Modern techniques for pituitary radiotherapy.Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors.Testicular germ cell tumours: predisposition genes and the male germ cell niche.Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecanClinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents.No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis.p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.Changing face of HPV related cancer in the UK.Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice.Mismatch repair as a prognostic marker for adjuvant therapy in colorectal cancer - how soon is now?Innovative Solutions for Clinical Trial Follow-up: Adding Value from Nationally Held UK Data.Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours.Intensity-modulated radiotherapy in anal cancer: where do we go from here?IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.Transdermal Oestradiol as a method of androgen suppression for Prostate Cancer within the STAMPEDE Trial Platform.Modern Challenges of Cancer Clinical Trials.Anal cancer: different epidemiological and clinical definitions.Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation.Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical Radiotherapy.Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse.Treating IIA/B Seminoma With Combination Carboplatin and RadiotherapyTreating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapyEpidermal growth factor receptor and the changing face of oropharyngeal cancerAspirin as a treatment for cancerRemote follow-up strategies after cancer treatment: a lot of opportunities
P50
Q31116008-FB43FC4B-993C-49CF-A119-8D9679EA4C63Q34627796-56079DFE-D703-452C-9EAB-D0D4AC72F936Q36429467-19927B13-4B11-4409-9C6F-33D859F0E3FBQ37267373-EFCC9D25-B42C-4BE0-8553-8F6B22F47ADEQ37385388-DBEB35A8-E7C5-472A-A652-034C7C7386A8Q37853838-E6896516-7C43-4F05-BAF1-2E55EA37ED0BQ37959718-4BA0532E-9EE8-4B14-A414-A6134471BEECQ38025707-89977CC9-6BCE-4AFB-86FB-ACACE1577515Q38927275-45B4C8C0-ECE0-4C67-A0D7-E77CCDD27CE7Q39931854-7848E120-29DC-462A-82C5-253292B76375Q40161797-FEA43991-6610-4DBF-9018-3A1466D03384Q41471597-14DE57DD-4FC7-4365-98D0-1854EAD9F094Q42270896-A1AE901C-0A27-4805-9543-A5EA3850B9D5Q44254511-8FCEEF41-70FF-4708-A0B3-C35A8A0E2A18Q44671444-BD00E44E-1C7B-4706-AE46-02234538B33EQ44834334-DA3531F6-1938-411C-8044-CDB186AE2C43Q45934102-FD611A9D-002F-470F-AAEE-DB17684D68A9Q46315247-29D5C359-A811-4752-A0C1-C0C15763069AQ46372046-6886AB64-8215-4403-A968-61834B688F9BQ48262511-500CE4E9-817A-4C9F-99F6-8D2F5B436B17Q49503108-ED20FDA7-C54D-48E3-AABA-9F8EEDCBE310Q50077928-752EBC4B-2C7C-41CF-9A23-FF00790EA561Q50100004-AD9E16F8-2542-4E0C-9629-93053214A297Q52838963-0DDEE981-E42A-41F9-8052-A3D3A6ADED3FQ52861613-C51FC297-8447-42D8-BC00-44D94C960351Q54621692-4E89A28A-1D09-479E-AFD9-D9CB40F01025Q63966741-79CD42BB-2B35-443E-B901-50CB772DF545Q79870347-5F33F2A3-29A5-41E0-A87E-D7F31F7D21D1Q83440976-B8300BEB-CD04-4B2B-8209-5862B8B31B83Q86558163-DF31E496-0DAE-4C5F-A430-3C759B51A0BFQ88164335-DBD1B1D1-66DB-47ED-9CEB-DF14BF8F8BF8
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1859-7012
@en
name
Duncan C Gilbert
@ast
Duncan C Gilbert
@en
Duncan C Gilbert
@es
Duncan C Gilbert
@nl
type
label
Duncan C Gilbert
@ast
Duncan C Gilbert
@en
Duncan C Gilbert
@es
Duncan C Gilbert
@nl
prefLabel
Duncan C Gilbert
@ast
Duncan C Gilbert
@en
Duncan C Gilbert
@es
Duncan C Gilbert
@nl
P106
P1153
14014363300
P31
P496
0000-0003-1859-7012